Pharmacological Potential of Methylxanthines: Retrospective Analysis and Future Expectations
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Additions and Deletions to the Drug Product List
Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690 -
The Adenosinergic System a Non-Dopaminergic Target in Parkinson’S Disease
springer.com Biomedicine : Neurosciences Morelli, M., Simola, N., Wardas, J. (Eds.) The Adenosinergic System A Non-Dopaminergic Target in Parkinson’s Disease Comprehensive book that discusses all the aspects of this class of drugs in relation to Parkinson's Disease Includes a review on the history of istradefylline Includes a review on urate as a biomarker and neuroprotectant Adenosine A2A receptor antagonists have shown great promise in the treatment of Parkinson's Disease and alleviation of symptoms. This bookaddresses various aspects of this class of drugs from their chemical development to their clinical use. Among the many insightful chapters contained in this book, there are three unique reviews that have not previously been published in any format: (1) a history of istradefylline, the first A2A antagonist approved for treatment of Parkinson's Disease, (2) an overview of neuroimaging studies in human death and disease and (3) a study of urate as a possible biomarker and neuroprotectant. Springer 1st ed. 2015, XII, 337 p. 41 Order online at springer.com/booksellers 1st illus., 31 illus. in color. Springer Nature Customer Service Center LLC edition 233 Spring Street New York, NY 10013 USA Printed book T: +1-800-SPRINGER NATURE Hardcover (777-4643) or 212-460-1500 [email protected] Printed book Hardcover ISBN 978-3-319-20272-3 $ 199,99 Available Discount group Professional Books (2) Product category Contributed volume Series Current Topics in Neurotoxicity Other renditions Softcover ISBN 978-3-319-37186-3 Softcover ISBN 978-3-319-20274-7 Prices and other details are subject to change without notice. -
Neonatal Intensive Care Drug Therapy Update: a Bibliography
LWW/JPNN AS310-13 July 28, 2004 23:11 Char Count= 0 J Perinat Neonat Nurs Vol. 18, No. 3, pp. 292–306 c 2004 Lippincott Williams & Wilkins, Inc. Neonatal Intensive Care Drug Therapy Update: A Bibliography Jason Sauberan, PharmD BIBLIOGRAPHY I. Overview A. Clark RH, Bloom BT, Gerstmann DR Medications Used in Neonatal Intensive Care Units—A Descriptive Study [abstract 3047]. In: Program and abstracts of the 2004 Pediatric Academic Societies’ Annual Meeting, San Francisco, CA. B. Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, Berkovitch M. Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol. 2002 Feb;19(2):67–72. C. O’Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002 Nov;110(5):e52. D. Committee on Drugs. American Academy of Pediatrics. Uses of drugs not described in the package insert (off-label uses). Pediatrics. 2002 Jul;110(1 Pt 1):181–3. II. Anti-infectives A. Linezolid 1. Deville JG, Adler S, Azimi PH, Jantausch BA, Morfin MR, Beltran S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S158–63. 2. Vo M, Cirincione BB, Rubino CM, Jungbluth GL. Pharmacokinetics of Linezolid in Neonates and Young Infants [abstract A-1409]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. -
Doxofylline, a Novofylline Inhibits Lung Inflammation Induced By
Pulmonary Pharmacology & Therapeutics 27 (2014) 170e178 Contents lists available at ScienceDirect Pulmonary Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/ypupt Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse Yanira Riffo-Vasquez*, Francis Man, Clive P. Page Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, UK article info abstract Article history: Rational: Doxofylline is a xanthine drug that has been used as a treatment for respiratory diseases for Received 20 December 2013 more than 30 years. In addition to doxofylline being a bronchodilator, some studies have indicated that Received in revised form doxofylline also has anti-inflammatory properties, although little is known about the effect of this drug 30 December 2013 on lung inflammation. Accepted 2 January 2014 Objectives: We have investigated the actions of doxofylline against the effects of Escherichia coli LPS in the lungs of BALB/c mice. Keywords: Methods: Animals have been treated with doxofylline (0.1, 0.3 and 1 mg/kg i.p.) 24, -and 1 h before, and Doxofylline m Neutrophils 6 h after intra-nasal instillation of LPS (10 g/mouse). Readouts were performed 24 h later. fi LPS Results: Doxofylline at 1 and 0.3, but not at 0.1 mg/kg, signi cantly inhibit neutrophil recruitment to the Lung lung induced by LPS (LPS: 208.4 Æ 14.5 versus doxofylline: 1 mg/kg: 106.2 Æ 4.8; 0.3 mg/kg: 4 Inflammation 105.3 Æ 10.7 Â 10 cells/ml). Doxofylline significantly inhibited IL-6 and TNF-a release into BAL fluid in Mice comparison to LPS-treated animals (LPS: 1255.6 Æ 143.9 versus doxofylline 1 mg/kg: 527.7 Æ 182.9; 0.3 mg/kg: 823.2 Æ 102.3 pg/ml). -
(Trental) Does Not Inhibit Dipyridamole-Induced Coronary Hyperemia: Implications for Dipyridamole-Thaffium-20 1 Myocardial Imaging
Pentoxifyffine (Trental) Does Not Inhibit Dipyridamole-Induced Coronary Hyperemia: Implications for Dipyridamole-Thaffium-20 1 Myocardial Imaging Kenneth A. Brown and Bryan K. Slinker Cardiology Unit ofihe University of Vermont College ofMedicine, Burlington, Vermont been found to be efficacious in the treatment of inter Dipyndamole-thallium-201imagingis often performedin mittent claudication because of its unique hemorrheo patientsunableto exercisebecauseof peripheralvascular logic effects (9). Thus, many patients with peripheral disease.Manyof these patientsare taking pentoxifylline vascular disease who undergo dipyridamole-thallium (Trental),a methylxanthinederivativewhichmayimprove 201 imaging may be taking pentoxifylline at the time intermittent claudication. Whether pentoxifylline inhibits di of their study. Although in vitro data from rat fat cells pyndamole-inducedcoronaryhyperamialike other math and hippocampal slices suggest that pentoxifylline is a ylxanthinas such as theophyllina and should be stopped much weaker adenosine antagonist than theophylline prior to dipyndamole-thallium-201 imaging is unknown. (7), it is not known whetherpentoxifylline significantly Therefore,we studiedthe hyperemicresponseto dipyn damolein sevenopen-chestanesthetizeddogs after pre inhibits dipyridamole-induced coronary hyperemia in treatmentwith either pantoxifylline(0, 7.5, or i 5 mg/kg vivo and should, therefore, be stopped prior to dipyri i.v.) or theophyllina(3 mg/kg i.v.). Baseline circumflex damole-thallium-20l imaging. Hence, we studied the -
Tainted Products Marketed As Dietary Supplements
Tainted Products Marketed as Dietary Supplements Jason Humbert, MPS Nicole Kornspan, MPH Regulatory Operations Officer Consumer Safety Officer Food and Drug Administration Office of Regulatory Affairs Health Fraud Branch Overview • Definition of health fraud • Tainted products – then and now • Dietary Supplement Health and Education Act of 1994 (DSHEA) • Concerns related to tainted products • Enforcement challenges • Resources 2 FDA Definition of Health Fraud • The deceptive promotion, advertisement, or sale of products as being effective to diagnose, prevent, cure, treat, or mitigate disease, or to provide a beneficial effect on health, but which have not been scientifically proven safe and effective for such purposes. • May be deliberate, or done without adequate knowledge or understanding of the product. 3 Health Fraud: What are the Risks? • Direct health hazard: product is likely to cause injury, death or other serious adverse effect when used as directed • Indirect health hazard: product poses no direct hazard, but consumer is likely to delay or discontinue appropriate medical treatment by relying on product. 4 4 Tainted Products – Then • 1865-1906: “Golden age” of American quackery • 1905 estimate: 50,000 patent medicines – Drugs were bought and sold like any other consumer good. – Contain dangerous, addictive, misidentified ingredients – Alcohol, cocaine, heroin, opium, without restrictions – Did not have to disclose ingredients – No warnings about misuse – Manufacturer not listed 5 Tainted Products – Now 6 6 Dietary Supplement -
Summary of Product Characteristics
Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Cardisure 3.5 mg/ml Oral Solution for Dogs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Active substance: Pimobendan 3.5 mg Excipients: Benzyl alcohol (E1519) 1.0 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Oral Solution. Clear, colourless, semi-viscous liquid. 4 CLINICAL PARTICULARS 4.1 Target Species Dogs. 4.2 Indications for use, specifying the target species For the treatment of canine congestive heart failure originating from valvular insufficiency (mitral and/or tricuspid regurgitation) or dilated cardiomyopathy. 4.3 Contraindications Do not use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). Do not use in dogs with severe impairment of liver function, as pimobendan is metabolised mainly via the liver. Do not use in cases of known hypersensitivity to the active substance or to any of the excipients. 4.4 Special warnings for each target species None known. 4.5 Special precautions for use Special precautions for use in animals The blood glucose should be tested regularly during treatment in dogs with existing diabetes mellitus. Monitoring of cardiac function and morphology is recommended in animals treated with pimobendan (See also section 4.6). Special precautions to be taken by the person administering the veterinary medicinal product to animals Accidental ingestion, especially by a child, may lead to the occurrence of tachycardia, orthostatic hypotension, flushing of the face and headaches. -
Impact of Doxofylline in COPD a Pairwise Meta-Analysis
King’s Research Portal DOI: 10.1016/j.pupt.2018.04.010 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Cazzola, M., Calzetta, L., Rogliani, P., Page, C., & Matera, M. G. (2018). Impact of doxofylline in COPD: A pair- wise meta-analysis . PULMONARY PHARMACOLOGY AND THERAPEUTICS, 51. https://doi.org/10.1016/j.pupt.2018.04.010 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. -
Screening of Phosphodiesterase-5 Inhibitors and Their Analogs in Dietary Supplements by Liquid Chromatography–Hybrid Ion Trap–Time of Flight Mass Spectrometry
molecules Article Screening of Phosphodiesterase-5 Inhibitors and Their Analogs in Dietary Supplements by Liquid Chromatography–Hybrid Ion Trap–Time of Flight Mass Spectrometry 1,2, 1,3, 4 5 3 Unyong Kim y, Hyun-Deok Cho y, Myung Hee Kang , Joon Hyuk Suh , Han Young Eom , Junghyun Kim 6, Sumin Seo 1, Gunwoo Kim 1, Hye Ryoung Koo 1, Nary Ha 1, Un Tak Song 1 and Sang Beom Han 1,* 1 Department of Pharmaceutical Analysis, College of Pharmacy, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul 06974, Korea; [email protected] (U.K.); [email protected] (H.-D.C.); [email protected] (S.S.); [email protected] (G.K.); [email protected] (H.R.K); [email protected] (N.H.); [email protected] (U.T.S.) 2 Biocomplete Co., Ltd., 272 Digital-ro, Guro-gu, Seoul 08389, Korea 3 Bioanalysis and Pharmacokinetics Study Group, Korea Institute of Toxicology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, Korea; [email protected] 4 Agro-Livestock and Fishery Products Division, Busan Regional Korea Food and Drug Administration, 222 Geoje-daero, Yunje-gu, Busan 47537, Korea; [email protected] 5 Department of Food Science and Human Nutrition, Citrus Research and Education Center, University of Florida, 700 Experiment Station Rd, Lake Alfred, FL 33850, USA; joonhyuksuh@ufl.edu 6 Forensic Toxicology Division, National Forensic Service, 10 Ipchoon-ro, Wonju, Gangwon-do 26460, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-2-820-5596 These authors contributed equally to this work. y Received: 22 May 2020; Accepted: 9 June 2020; Published: 12 June 2020 Abstract: An accurate and reliable method based on ion trap–time of flight mass spectrometry (IT–TOF MS) was developed for screening phosphodiesterase-5 inhibitors, including sildenafil, vardenafil, and tadalafil, and their analogs in dietary supplements. -
Caffeine and Adenosine
Journal of Alzheimer’s Disease 20 (2010) S3–S15 S3 DOI 10.3233/JAD-2010-1379 IOS Press Review Article Caffeine and Adenosine Joaquim A. Ribeiro∗ and Ana M. Sebastiao˜ Institute of Pharmacology and Neurosciences, Faculty of Medicine and Unit of Neurosciences, Institute of Molecular Medicine, University of Lisbon, Lisbon, Portugal Abstract. Caffeine causes most of its biological effects via antagonizing all types of adenosine receptors (ARs): A1, A2A, A3, and A2B and, as does adenosine, exerts effects on neurons and glial cells of all brain areas. In consequence, caffeine, when acting as an AR antagonist, is doing the opposite of activation of adenosine receptors due to removal of endogenous adenosinergic tonus. Besides AR antagonism, xanthines, including caffeine, have other biological actions: they inhibit phosphodiesterases (PDEs) (e.g., PDE1, PDE4, PDE5), promote calcium release from intracellular stores, and interfere with GABA-A receptors. Caffeine, through antagonism of ARs, affects brain functions such as sleep, cognition, learning, and memory, and modifies brain dysfunctions and diseases: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Epilepsy, Pain/Migraine, Depression, Schizophrenia. In conclusion, targeting approaches that involve ARs will enhance the possibilities to correct brain dysfunctions, via the universally consumed substance that is caffeine. Keywords: Adenosine, Alzheimer’s disease, anxiety, caffeine, cognition, Huntington’s disease, migraine, Parkinson’s disease, schizophrenia, sleep INTRODUCTION were considered out of the scope of the present work. For more detailed analysis of the actions of caffeine in Caffeine causes most of its biological effects via humans, namely cognition, dementia, and Alzheimer’s antagonizing all types of adenosine receptors (ARs). -
Effect of Theophylline and Enprofylline on Bronchial Hyperresponsiveness
Thorax: first published as 10.1136/thx.44.12.1022 on 1 December 1989. Downloaded from Thorax 1989;44:1022-1026 Effect of theophylline and enprofylline on bronchial hyperresponsiveness G H KOETER, J KRAAN, M BOORSMA, J H G JONKMAN, TH W VAN DER MARK From the Department ofPulmonology and Lung Function, University Hospital, Groningen; Pharma Bio Research, Assen; and Astra Pharmaceutica, Rijswijk, The Netherlands ABSTRACT The effect of increasing intravenous doses of theophylline and enprofylline, a new xanthine derivative, on bronchial responsiveness to methacholine was studied in eight asthmatic patients. Methacholine provocations were carried out on three days before and after increasing doses of theophylline, enprofylline, and placebo, a double blind study design being used. Methacholine responsiveness was determined as the provocative concentration of methacholine causing a fall of 20% in FEV, (PC20). The patients were characterised pharmacokinetically before the main study to provide an individual dosage scheme for each patient that would provide rapid steady state plasma concentration plateaus of 5, 10, and 15 mg/l for theophylline and 1 25, 2 5, and 3-75 mg/l for enprofylline. Dose increments in the main study were given at 90 minute intervals. FEV, showed a small progressive decrease after placebo; it remained high in relation to placebo after both drugs and this effect was dose related. Methacholine PC20 values decreased after placebo; mean values were (maximum difference 2-0 and 1 7 higher after theophylline and enprofylline than after placebo copyright. doubling doses of methacholine); the effect of both drugs was dose related. Thus enprofylline and theophylline when given intravenously cause a small dose related increase in FEV1 and methacholine PC20 when compared with placebo. -
Dynamic Analysis of Cardiovascular Drugs Data
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2014, 6(5):1517-1520 ISSN : 0975-7384 Research Article CODEN(USA) : JCPRC5 Dynamic analysis of cardiovascular drugs data Humei Yang and SunShi The Affiliated Hospital of Qingdao University Medical College , China _____________________________________________________________________________________________ ABSTRACT Cardiovascular disease is an important disease which is a serious hazard to human health, not only that, but the cause is still quite complicated. Therefore, it is very important to carry out research work of cardiovascular drugs in the medical profession. In this article, the money amount sequence method and DDD number sequence method were used to statistically analyze the data of cardiovascular drugs which were purchased by patients in a hospital in Shanghai in 2010-2013 year. The data of cardiovascular drugs second-class hospitals and upper-class hospitals in Shanghai included the drug varieties, prescription medication, the amount of money, which were statistically analyzed in order to provide recommendations for future cardiovascular medication guide. Through this research, we have come to the result that the money of cardiovascular drugs accounts greater of the amount of all of the drugs in the second-class hospitals than that in the upper-class hospitals, and cardiovascular medication amounts, prescriptions, etc of the second-class hospitals and upper-class hospitals had increased than before. Calcium antagonists and angiotensin ⅱ receptor antagonist drugs led occupation, as well as a small amount of varieties of drugs had gone into the top 10 amounts .As for cardiovascular drugs, foreign markets occupy a major market. That is to say that between different levels of hospitals there is some difference in cardiovascular drug use, but the drugs with good effects are already the first choice.